SUBSTANCE P (SP) has been implicated in immune responses and could inc
rease glutamate release, and inflammatory reactions are known to be ab
le to potentiate ischemic damage. We have previously found that SP was
over-expressed in cerebral ischemia and speculated that SP may play a
role in exacerbating ischemic damage. In this study, we examined whet
her a neurokinin-1 (NK-1) receptor antagonist, SR140333, would have an
effect on brain ischemia. Intracerebroventricular (i.c.v.) administra
tion of SR140333 (30 mu g) markedly reduced (37.1 +/- 7.8%,P < 0.001)
infarct volume measured 24 h after focal cerebral ischemia in the rat.
The SR140333-treated group also exhibited a significantly improved ne
urological function reflected by the neurological deficit score. The r
esults represented the first demonstration that a NK-I receptor antago
nist may be a novel type of drug for treatment of cerebral ischemia.